Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out
March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Friday, November 30, 2012

Most Frequently Asked Questions (FAQ) by sufferers, and some Answers (A)

Most frequently asked questions (FAQ)
by sufferers:

  1. Where do I begin to find out what causes my odor/halitosis condition, and how can it be cured?
  2. Do I have Primary TMAU (TMAU1)
  • Do I have Secondary TMAU (TMAU2)?

  • What about the 70+% who test negative for TMAU1 & TMAU2? What do they have?

  • Could a microbial imbalance in my gut be the cause of odor symptoms?

  • Could I have more than one FMO3 deficiency, which then would compromise multiple metabolic pathways resulting in an odorous chemical buildup in my body?

  • What about women’s needs – hormonal changes, vaginal microflora alterations possibly due to changes in pH in mucosal tissue and FMO3 deficiencies?

  • In an effort to find answers to these questions, sufferers are usually recommended to do the following:
    1. Consult with your physician and/or dentist to rule out the already known causes of these symptoms.
    2. When your physician cannot find a cause, the TMAU Test is recommended. If you decide to do your TMAU Test through MEBO, your urine sample will be analyzed with a High performance liquid chromatography (HPLC).
    3. What would TMAU Test results performed by HPLC look like? See

    of 64 patients who have done the TMAU Test with HPCL. Please note that the three columns, TMA, TMAO, and TMA/TMAO RATIO, have been individually sorted from highest to lowest results, and therefore, reading across a row would not represent the results of any one particular patient.
  • Where would your figures fall in the 64 patient TMAU Test Results analyzed with HPLC? If you would like to get answers to some of these questions, you can fill out the

    to obtain cost information of the test ($150) and shipping cost to/from your address. There would be no additional expense for your test experience after this initial payment - no additional fees or hidden costs.

    How results are interpreted:
    • TMAU1 can only be truly confirmed by FMO3 enzyme analysis (difficult because a liver biopsy would be needed) or DNA analysis.
    • TMAU2 must be a diagnosis by exclusion.
    • TMA-oxide can be used as a guide, but is not diagnostic for TMAU2.
    • Therefore, if TMA is increased and TMA-oxide is normal and (as in many cases) FMO3 is not proven to be affected the diagnosis must be TMAU2 by exclusion.
    • If TMA is normal and TMA-oxide is significantly high, suggest a re-test following a choline load.
      Nigel Manning, Principal Clinical Scientist
      Department of Metabolic Biochemistry at Sheffield Children's Hospital, UK

  • What if my results fall in the larger black area of the chart results (negative for TMAU1 & TMAU2)? As you can see, the majority of sufferers, approximately 70%, fall in the negative for Primary and Secondary TMAU combined category. In fact, 95% fall in the negative for Primary TMAU category.

    This is a clear indication that a great deal of exploratory research needs to be carried out to discover other causes.

    MEBO is committed to pursuing research, especially exploratory research, the type of studies that are merely formative, for the purpose of gaining new insights, discovering new ideas, and increasing knowledge into the various causes of uncontrollable body and breath odor conditions.

  • María

    María de la Torre
    Founder and Executive Director

    A Public Charity
    MEBO's Blog (English)
    El Blog de MEBO (español)
    MEBO Brasil - Blog (Portuguese)

    SUPPORT THE MEBO MISSION: Click Amazon button at right sidebar of this blog when shopping online for the holidays
    at no extra cost to you.
    MEBO gets small commission from Amazon.

    Please use your credit card to make your donation to MEBO.

    Subscribe for latest posts : Enter your email address:

    Delivered by FeedBurner

    A EURORDIS and NORD Member Organization


    Post a Comment